| Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma (NCT05422027) | Xia Zhongjun | 2022-07-25 |
| The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors (NCT05131815) | Cedars-Sinai Medical Center | 2022-07-25 |
| Patient With MMRR Treated With Belantamab Mafotidine on Monotherapy (NCT05393024) | Fondazione EMN Italy Onlus | 2022-07-22 |
| Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM (NCT07150091) | GlaxoSmithKline | 2022-07-19 |
| SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease (NCT05900882) | The First Affiliated Hospital with Nanjing Medical University | 2022-07-15 |
| Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1) (NCT05396885) | Kite, A Gilead Company | 2022-07-15 |
| ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM) (NCT05632380) | Institute of Hematology & Blood Diseases Hospital, China | 2022-07-14 |
| Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM (NCT05594797) | Hrain Biotechnology Co., Ltd. | 2022-07-12 |
| Non-interventional Study to Evaluate Patient and Healthcare Provider Satisfaction of Daratumumab Use in the Treatment of First-line Daratumumab, Lenalidomide, Dexamethasone (DRd) Multiple Myeloma Patients in Germany Depending on Application Route (sc or iv) (NCT05284591) | iOMEDICO AG | 2022-07-06 |
| Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma (NCT05722405) | Second Affiliated Hospital, Zhejiang University, School of Medicine | 2022-07-01 |
| A Real-World Study of Bispecific Antibodies in Multiple Myeloma (NCT06359067) | Assistance Publique - Hôpitaux de Paris | 2022-07-01 |
| Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury (NCT05429515) | Peking Union Medical College Hospital | 2022-07-01 |
| A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma (NCT05183139) | Takeda | 2022-06-30 |
| Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (NCT04975997) | Celgene | 2022-06-23 |
| A Study of MCARH109 and MCARH125 in People With Multiple Myeloma (NCT05431608) | Memorial Sloan Kettering Cancer Center | 2022-06-20 |
| Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab (NCT05053607) | Pack Health | 2022-06-17 |
| Iberdomide Maintenance Therapy in Patients With Multiple Myeloma (NCT05177536) | University of Nebraska | 2022-06-14 |
| Study of Dual Targeted CD19/BCMA FASTCART GC012F in Relapsed/ Refractory Multiple Myeloma (NCT05412329) | Shanghai Changzheng Hospital | 2022-06-13 |
| MargheRITA (Remote Intelligence for Therapeutic Adherence) (NCT05260203) | Advice Pharma Group srl | 2022-06-04 |
| Impact of Paramedical Consultations in Oncological Supportive Care in Outpatients With Multiple Myeloma (NCT05355987) | Centre Henri Becquerel | 2022-06-03 |
| Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma (NCT05336383) | M.D. Anderson Cancer Center | 2022-05-31 |
| 89Zr-labeled NY008 PET Imaging in Patients (NCT05655676) | Affiliated Hospital of Jiangnan University | 2022-05-25 |
| A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant (NCT05393804) | Memorial Sloan Kettering Cancer Center | 2022-05-20 |
| Diagnostic Performance of Spot Urine Sample for the Monoclonal Components Detection in Patients With Multiple Myeloma (NCT05208086) | Intergroupe Francophone du Myelome | 2022-05-18 |
| Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy (NCT05414162) | University Hospital, Bonn | 2022-05-16 |
| Clinical Research of Pomalidomide Maintenance Therapy for Primary Multiple Myeloma (NCT05378971) | LanZhou University | 2022-05-15 |
| Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma (NCT05199311) | Hackensack Meridian Health | 2022-05-13 |
| A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma (NCT05347485) | Janssen Scientific Affairs, LLC | 2022-05-13 |
| Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. (NCT04771572) | Newave Pharmaceutical Inc | 2022-05-08 |
| P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma (NCT04960579) | Poseida Therapeutics, Inc. | 2022-05-05 |
| Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies (NCT05191472) | Alfred Chung, MD | 2022-05-03 |
| Cohort Construction and Prognostic Model Construction for Multiple Myeloma (NCT06366802) | The First Affiliated Hospital of Soochow University | 2022-05-03 |
| cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease (NCT05366881) | Adela, Inc | 2022-05-03 |
| A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma (NCT04700176) | Hackensack Meridian Health | 2022-05-02 |
| Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma (NCT05289492) | iTeos Therapeutics | 2022-05-01 |
| A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor (NCT05298683) | Hellenic Society of Hematology | 2022-05-01 |
| Safety and Efficacy of Anti-BCMA/GPRC5D CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma(rr/MM) (NCT05509530) | Xuzhou Medical University | 2022-05-01 |
| Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT) (NCT05354557) | Memorial Sloan Kettering Cancer Center | 2022-04-26 |
| Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma (NCT05294055) | Institute of Hematology & Blood Diseases Hospital, China | 2022-04-26 |
| A New Study Evaluating the Activity of Modular CAR T for mYeloma (NCT04795882) | University College, London | 2022-04-22 |
| Efficacy and Safety of PEG-rhG-CSF Injection for Neutrophil Reconstitution Following AHSCT in Lymphoma/Multiple Myeloma (NCT06060080) | Yao Liu | 2022-04-22 |
| Prospective Evaluation of the Prognostic Impact of Measurable Residual Disease (MRD) Within a Phase III Study Comparing a Fixed Duration Therapy Versus Continuous Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Requiring a First Salvage Treatment. (NCT05203003) | Assistance Publique - Hôpitaux de Paris | 2022-04-22 |
| Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant (NCT05271630) | H. Lee Moffitt Cancer Center and Research Institute | 2022-04-20 |
| A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible (NCT05280275) | Hellenic Society of Hematology | 2022-04-13 |
| Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions (NCT05361694) | University of Miami | 2022-04-12 |
| Early Integration of Palliative and Supportive Care in Cellular Therapy (NCT05190653) | Alberta Health Services, Calgary | 2022-04-08 |
| Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma (NCT05123131) | Cancer Trials Ireland | 2022-04-01 |
| A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment (NCT05147493) | Hellenic Society of Hematology | 2022-04-01 |
| A Study of Fully Human BCMA CAR-T (CT103A) in Patients With Newly Diagnosed High-risk Multiple Myeloma (FUMANBA-2) (NCT05181501) | Nanjing IASO Biotechnology Co., Ltd. | 2022-04-01 |
| A Study of CAR-T Cells Targeting Both BCMA and GPRC5D in Treatment of Relapsed or Refractory Multiple Myeloma (NCT05325801) | Zhejiang University | 2022-04-01 |
| Daratumumab Provided at Home Experience An Open, Single-center, Mixed-method Project. (NCT05306587) | Thomas Lund | 2022-04-01 |
| Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant (NCT05317416) | Pfizer | 2022-03-25 |
| Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy (NCT05064787) | Pack Health | 2022-03-11 |
| A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel (NCT05201781) | Janssen Research & Development, LLC | 2022-03-09 |
| A Head-to-head Comparative Study of 18F-PSMA-1007 PET/CT and 18F-FDG PET/CT Imaging in Multiple Myeloma (NCT05448404) | First Hospital of China Medical University | 2022-03-08 |
| Assessing the Impact of a Financial Navigation Program for Patients With Multiple Myeloma (NCT05448196) | Abramson Cancer Center at Penn Medicine | 2022-03-04 |
| Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma (NCT05064358) | GlaxoSmithKline | 2022-03-03 |
| PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma (NCT05172596) | Novartis Pharmaceuticals | 2022-03-03 |
| A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) (NCT04988555) | Sumitomo Pharma America, Inc. | 2022-02-28 |
| A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class Exposure (NCT05217082) | Bristol-Myers Squibb | 2022-02-22 |
| Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma (NCT05002816) | Yale University | 2022-02-21 |
| Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma (NCT05145400) | UNC Lineberger Comprehensive Cancer Center | 2022-02-18 |
| A Study of Real Life Treatment for Multiple Myeloma (MM) (NCT04985643) | Takeda | 2022-02-18 |
| Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial (NCT03941860) | National Cancer Institute (NCI) | 2022-02-16 |
| All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma (NCT06956170) | GlaxoSmithKline | 2022-02-10 |
| To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM (NCT05302648) | Hrain Biotechnology Co., Ltd. | 2022-02-09 |
| Patient and Care Partner Experiences Living With Multiple Myeloma (PaCE-MM) (NCT05276622) | UNC Lineberger Comprehensive Cancer Center | 2022-02-08 |
| Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma (NCT04879043) | Heidelberg Pharma AG | 2022-02-07 |
| Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT (NCT05493800) | MitoImmune Therapeutics | 2022-02-01 |
| Financial Difficulty in Patients With Blood Cancer (NCT05212233) | UNC Lineberger Comprehensive Cancer Center | 2022-01-27 |
| Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM (NCT04941937) | Juan Du | 2022-01-27 |
| Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL (NCT05153330) | Biomea Fusion Inc. | 2022-01-24 |
| Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma (NCT04895410) | AbbVie | 2022-01-17 |
| A Perspective Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment (NCT06109233) | FengYan Jin | 2022-01-10 |
| Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (NCT04835129) | Medical College of Wisconsin | 2022-01-10 |
| Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma (NCT05032820) | Medical College of Wisconsin | 2022-01-05 |
| Daratumumab-containing Induction Effects on Stem Cells Mobilization, colLection and Engraftment in Newly Diagnosed Multiple MyelomA Patients. (NCT05835726) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2022-01-01 |
| Cost-Utility Analysis of Home-based Versus Hospital-based Chemotherapy in Multiple Myeloma: Case of Carfilzomib (NCT05184595) | Central Hospital, Nancy, France | 2022-01-01 |
| Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial) for Minimal Residual Disease (MRD (NCT05192122) | University of Illinois at Chicago | 2021-12-31 |
| Using Mass Spectrometry (EasyM) Detecting Minimal Residual Disease (MRD) in Multiple Myeloma (NCT05536700) | Institute of Hematology & Blood Diseases Hospital, China | 2021-12-31 |
| A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies (NCT05055791) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2021-12-29 |
| A Study Evaluating Safety, Tolerability and Clinical Activity of FHND6091 in Patients With Multiple Myeloma (NCT05271682) | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. | 2021-12-22 |
| Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT) (NCT05130827) | Memorial Sloan Kettering Cancer Center | 2021-12-21 |
| A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma. (NCT05228470) | Pfizer | 2021-12-21 |
| Novel Drugs After Allo-HSCT in Patients With Multiple Myeloma (NCT04506320) | Gruppo Italiano Trapianto di Midollo Osseo | 2021-12-17 |
| Follow-up of Patients With Multiple Myeloma in the West-Occitanie Region "Living With a Myeloma in West-Occitanie" (NCT04888039) | University Hospital, Toulouse | 2021-12-15 |
| Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer (NCT04731844) | University of Rochester | 2021-12-14 |
| MInimal Residual Disease Adapted Strategy (NCT04934475) | Intergroupe Francophone du Myelome | 2021-12-08 |
| A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM (NCT04786028) | Canadian Myeloma Research Group | 2021-12-08 |
| CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma. (NCT04667663) | Cancer Trials Ireland | 2021-12-08 |
| Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy (NCT04223661) | Attaya Suvannasankha | 2021-12-06 |
| BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma (NCT04617704) | Shanghai Changzheng Hospital | 2021-12-01 |
| Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT (NCT05218603) | PETHEMA Foundation | 2021-11-30 |
| Descartes-25 in Relapsed/Refractory Multiple Myeloma (NCT05113342) | Cartesian Therapeutics | 2021-11-25 |
| Improving Cognitive Function in Older Adults Undergoing Stem Cell Transplant (NCT04898790) | University of Nebraska | 2021-11-18 |
| CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases (NCT04662294) | Zhejiang University | 2021-11-18 |
| Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy (NCT04975555) | University of Alabama at Birmingham | 2021-11-15 |
| FT576 in Subjects With Multiple Myeloma (NCT05182073) | Fate Therapeutics | 2021-11-10 |
| Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma (NCT04892446) | Gilead Sciences | 2021-11-09 |
| Carfilzomib, Lenalidomide, and Dexamethasone Re-induction Followed by the 2nd ASCT in Multiple Myeloma Patients Relapsed After the 1st ASCT (NCT05497102) | Samsung Medical Center | 2021-11-08 |